Apellis Pharmaceuticals APLS 深 滬
等待開盤 12-15 09:30:00 美东时间
25.23
+0.265
+1.06%
華盛通- 最 高25.275
- 今 開24.93
- 成交量 158.19万股
- 最 低 24.45
- 昨 收 24.965
- 總市值 32.04亿
- 52周最高 35.57
- 市盈率 靜 --
- 換手率 1.25%
- 52周最低 16.10
- 委 比 -75.02%
- 總股本 1.27亿
- 歷史最高 94.75
- 量 比 0.61
- 振 幅 3.30%
- 歷史最低 11.45
- 每 手 1
- 風險率 4.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Apellis Pharmaceuticals Announces The The New England Journal of Medicine Published Phase 3 VALIANT Results For EMPAVELI In C3G And IC-MPGN Patients; Reports Robust And Clinically Meaningful Benefits Across All Three Key Markers Of Disease, 68% Reduction In Proteinuria, Stabilization Of Kidney Function, And Substantial Clearance Of C3 Deposits
Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Consistent results across
12-04 06:07
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
<p>Apellis Pharmaceuticals, Inc. announced that its management will participate in webcast fireside chats at Citi’s 2025 Global Healthcare Conference on December 2, 2025, at 2:30 p.m. ET, and at the Evercore 8th Annual Healthcare Conference on December 3, 2025, at 2:10 p.m. ET. The live webcasts and a 30-day replay will be available on the company’s website under the “Events and Presentations” page in the “Investors and Media” section. Apellis is...
11-25 12:00
This Undervalued Biotech Might Have Just Proven Its Star Drug's Staying Power
Apellis reports five-year Syfovre data showing up to 31% slower GA lesion growth, reinforcing strong long-term efficacy and analyst optimism.
11-13 02:36
Wolfe Research Initiates Coverage On Apellis Pharmaceuticals with Peer Perform Rating
Wolfe Research analyst Andy Chen initiates coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Peer Perform rating.
11-06 21:25
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
A Peek at Sarepta Therapeutics's Future Earnings
Sarepta Therapeutics (NASDAQ:SRPT) will release its quarterly earnings report o...
11-01 02:02
Baird Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $52
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target from $50 to $52.
10-31 20:24
Apellis Pharmaceuticals shares are trading lower. The company reported Q3 financial results.
Apellis Pharmaceuticals shares are trading lower. The company reported Q3 finan...
10-30 23:00
